Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

t, are included in cost of sales, $19.3 million are included in SG&A, and $4.4 million are included in R&D, partially offset by $9.0 million of income included in Other Income/Expense, net.

-  For the three months ended December 31, 2009, $5.1 million of these expenses, net, are included in cost of sales, $16.1 million are included in SG&A, $1.1 million are included in R&D, $11.7 million are included in Other Income/Expense, net, and the remainder represents an adjustment to amounts attributable to the noncontrolling interest.  

-  For the year ended December 31, 2010, $10.5 million of these expenses, net, are included in cost of sales, $48.9 million are included in SG&A, $8.3 million are included in R&D, $2.4 million are included in Other Income/Expense, and the remainder represents an adjustment to amounts attributable to the noncontrolling interest.

-  For the year ended December 31, 2009, $33.5 million of these expenses, net are included in cost of sales, $49.6 million are included in SG&A, $22.7 million are included in R&D, and $9.9 million are included in earnings attributable to the noncontrolling interest. Partially offsetting these costs are other revenue, consisting primarily of the acceleration of the recognition of revenue related to certain product development agreements, totaling $30.8 million, and other income related to the favorable reversal of restructuring reserves and a gain on the sale of a joint venture totaling, offset by a loss on the sale of a subsidiary totaling $13.3 million.

(d)  The tax effect is calculated assuming an annual adjusted effective tax rate for the resulting adjusted earnings, and results in an effective tax rate on adjusted earnings of 27% in 2010 and 30% in 2009 including the impact of any tax synergies.  Additionally, in the 2009 quarter and year presented above, includes an income tax benefit of approximately $65.0 million relate
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... The U.S. Department of Labor has ... Edwardsville as part of the Trade Adjustment Assistance Community ... co-administered by the Department of Labor and Department of ... Thomas E. Perez and Secretary of Education Arne Duncan ... grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Calif. and MONROVIA, Calif., Jan. 6, 2011 Amgen ... today that they will collaborate to develop XmAb ® ... and CD32b.  XmAb5871 is currently in late-stage preclinical development ... Under the terms of the agreement, Amgen has the ...
... SAN FRANCISCO, Jan. 6, 2011 Vista Partners ... Therapeutics, Inc. (Nasdaq: OPXA ) and raised ... Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday ... for the treatment of Multiple sclerosis , is now ...
... 6, 2011 BioInformatics, LLC announces the release of ... Technologies:  Market Insights for Life Science Suppliers (#10-005) This ... respond in a timely fashion to the rapidly changing ... LLC quantifies and characterizes the market for genetic analysis ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2BioInformatics, LLC New Market Report - Genomics Technologies 2
(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... , Jan. 24, 2013 /PRNewswire-iReach/ -- The companion diagnostics ... has become one of the most promising areas within ... companies are now entering the highly attractive market of ... developing a combination product. The explosive M&A trend in ...
... their mother,s diet during gestation and lactation were found to ... than those not exposed to the chemical, researchers at the ... BPA is a chemical most commonly found in the lining ... in many hard plastic bottles, including baby bottles, but many ...
... Researchers at the University of Pittsburgh School of ... key HIV protein. In findings published online today in ... this vulnerable spot could stop the virus from replicating, ... Previous research demonstrated that a small HIV protein ...
Cached Biology News:Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 2Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 3Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 4Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 5Female mice exposed to BPA by mothers show unexpected characteristics 2Female mice exposed to BPA by mothers show unexpected characteristics 3Pitt team finds 'Achilles Heel' of key HIV replication protein 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: